Valina L Dawson

List of Publications by Citations

367 papers	60,569 citations	121 h-index	243 g-index
412 ext. papers	68,465 ext. citations	11.2 avg, IF	7.47 L-index

#	Paper	IF	Citations
367	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
366	Neurotoxic reactive astrocytes are induced by activated microglia. *Nature*, **2017**, 541, 481-487	50.4	2875
365	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. *Cell Death and Differentiation*, **2018**, 25, 486-541	12.7	2160
364	Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. *Cell Death and Differentiation*, **2012**, 19, 107-20	12.7	1843
363	Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. *Science*, **2002**, 297, 259-63	33.3	1508
362	Molecular pathways of neurodegeneration in Parkinson's disease. *Science*, **2003**, 302, 819-22	33.3	1382
361	PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 378-83	11.5	1199
360	Molecular pathophysiology of Parkinson's disease. *Annual Review of Neuroscience*, **2005**, 28, 57-87	17	982
359	Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. *Science*, **2001**, 291, 2423-8	33.3	944
358	Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 16842-7	11.5	933
357	Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. *Nature Medicine*, **1997**, 3, 1089-95	50.5	923
356	Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. *Nature Medicine*, **1999**, 5, 1403-9	50.5	906
355	Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 13354-9	11.5	835
354	A novel neuronal messenger molecule in brain: the free radical, nitric oxide. *Annals of Neurology*, **1992**, 32, 297-311	9.4	768
353	PARIS (ZNF746) repression of PGC-1 contributes to neurodegeneration in Parkinson's disease. *Cell* , **2011**, 144, 689-702	56.2	667
352	S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. *Science*, **2004**, 304, 1328-31	33.3	656
351	Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. *Cell Death and Differentiation*, **2015**, 22, 58-73	12.7	643

350	Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. *Nature Medicine*, **2001**, 7, 1144-50	50.5	643
349	Genetic animal models of Parkinson's disease. *Neuron*, **2010**, 66, 646-61	13.9	602
348	Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 18314-9	11.5	571
347	Kinase activity of mutant LRRK2 mediates neuronal toxicity. *Nature Neuroscience*, **2006**, 9, 1231-3	25.5	540
346	Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. *Nature*, **1995**, 378, 383-6	50.4	533
345	Nitric oxide synthase in models of focal ischemia. *Stroke*, **1997**, 28, 1283-8	6.7	515
344	Poly(ADP-ribose) (PAR) polymer is a death signal. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 18308-13	11.5	494
343	Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. *Human Molecular Genetics*, **2007**, 16, 223-32	5.6	466
342	Diagnosis and treatment of Parkinson disease: molecules to medicine. *Journal of Clinical Investigation*, **2006**, 116, 1744-54	15.9	461
341	Transneuronal Propagation of Pathologic Synuclein from the Gut to the Brain Models Parkinson's Disease. *Neuron*, **2019**, 103, 627-641.e7	13.9	453
340	Role of AIF in caspase-dependent and caspase-independent cell death. *Oncogene*, **2004**, 23, 2785-96	9.2	441
339	Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. *Nature Genetics*, **1999**, 22, 110-4	36.3	440
338	Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. *Journal of Neuroscience*, **2005**, 25, 2002-9	6.6	431
337	Localization of LRRK2 to membranous and vesicular structures in mammalian brain. *Annals of Neurology*, **2006**, 60, 557-69	9.4	429
336	Nitric oxide neurotoxicity. *Journal of Chemical Neuroanatomy*, **1996**, 10, 179-90	3.2	422
335	Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. *Nature Medicine*, **2018**, 24, 931-938	50.5	413
334	Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. *Journal of Cell Biology*, **2002**, 158, 507-17	7.3	405
333	DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 14807-12	11.5	387

332	Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. *Human Molecular Genetics*, **2001**, 10, 919-26	5.6	387
331	Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. *Trends in Pharmacological Sciences*, **2004**, 25, 259-64	13.2	386
330	Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. *Science Translational Medicine*, **2012**, 4, 141ra90	17.5	381
329	T cells from patients with Parkinson's disease recognize Esynuclein peptides. *Nature*, **2017**, 546, 656-661	50.4	379
328	Oxidative stress and genetics in the pathogenesis of Parkinson's disease. *Neurobiology of Disease*, **2000**, 7, 240-50	7.5	371
327	Immunologic NO synthase: elevation in severe AIDS dementia and induction by HIV-1 gp41. *Science*, **1996**, 274, 1917-21	33.3	369
326	Pathological Esynuclein transmission initiated by binding lymphocyte-activation gene 3. *Science*, **2016**, 353,	33.3	364
325	Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 18676-81	11.5	359
324	Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. *Human Molecular Genetics*, **2005**, 14, 2063-73	5.6	348
323	Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 5774-9	11.5	333
322	Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. *Human Molecular Genetics*, **2008**, 17, 431-9	5.6	330
321	Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. *Nature Cell Biology*, **2008**, 10, 866-73	23.4	307
320	Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. *Nature Medicine*, **2010**, 16, 998-1000	50.5	303
319	Recent advances in the genetics of Parkinson's disease. *Annual Review of Genomics and Human Genetics*, **2011**, 12, 301-25	9.7	301
318	Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities. *British Journal of Pharmacology*, **2014**, 171, 2000-16	8.6	298
317	Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes. *Nucleic Acids Research*, **2008**, 36, 6959-76	20.1	298
316	Requirement for nitric oxide activation of p21(ras)/extracellular regulated kinase in neuronal ischemic preconditioning. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 436-41	11.5	298
315	Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. *PLoS ONE*, **2011**, 6, e18568	3.7	297

314	Nitric oxide in neurodegeneration. *Progress in Brain Research*, **1998**, 118, 215-29	2.9	296
313	Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. *Human Molecular Genetics*, **2005**, 14, 3801-11	5.6	288
312	Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). *Science Signaling*, **2011**, 4, ra20	8.8	286
311	Parkin-independent mitophagy requires Drp1 and maintains the integrity of mammalian heart and brain. *EMBO Journal*, **2014**, 33, 2798-813	13	284
310	Loss of locus coeruleus neurons and reduced startle in parkin null mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 10744-9	11.5	275
309	Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. *Human Molecular Genetics*, **1998**, 7, 783-90	5.6	269
308	Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. *Experimental Neurology*, **2009**, 218, 193-202	5.7	264
307	Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 17699-704	11.5	260
306	Parthanatos, a messenger of death. *Frontiers in Bioscience - Landmark*, **2009**, 14, 1116-28	2.8	259
305	Parkin and PINK1: much more than mitophagy. *Trends in Neurosciences*, **2014**, 37, 315-24	13.3	258
304	The role of parkin in familial and sporadic Parkinson's disease. *Movement Disorders*, **2010**, 25 Suppl 1, S32-9	7	253
303	Apoptosis-inducing factor substitutes for caspase executioners in NMDA-triggered excitotoxic neuronal death. *Journal of Neuroscience*, **2004**, 24, 10963-73	6.6	240
302	Manganese superoxide dismutase protects nNOS neurons from NMDA and nitric oxide-mediated neurotoxicity. *Journal of Neuroscience*, **1998**, 18, 2040-55	6.6	239
301	PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury. *Journal of Neurochemistry*, **2004**, 90, 1068-75	6	233
300	Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. *Neuropharmacology*, **1994**, 33, 1425-30	5.5	232
299	Neurobiology of nitric oxide. *Critical Reviews in Neurobiology*, **1996**, 10, 291-316		228
298	Understanding microRNAs in neurodegeneration. *Nature Reviews Neuroscience*, **2009**, 10, 837-41	13.5	226
297	Mitochondrial and nuclear cross talk in cell death: parthanatos. *Annals of the New York Academy of Sciences*, **2008**, 1147, 233-41	6.5	222

296	Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. *Human Molecular Genetics*, **2005**, 14, 71-84	5.6	218
295	In vitro and in vivo effects of genistein on murine alveolar macrophage TNF alpha production. *Cellular and Molecular Neurobiology*, **1999**, 23, 231-9	4.6	205
294	Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. *Journal of Neuroscience*, **2005**, 25, 7968-78	6.6	204
293	Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 10209-14	11.5	203
292	Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents. *Journal of Biological Chemistry*, **2007**, 282, 16441-53	5.4	202
291	Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. *Journal of Neuroscience*, **2005**, 25, 5544-52	6.6	202
290	Sulfhydration mediates neuroprotective actions of parkin. *Nature Communications*, **2013**, 4, 1626	17.4	201
289	Neuroprotection by pharmacologic blockade of the GAPDH death cascade. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 3887-9	11.5	200
288	Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 16691-6	11.5	199
287	Mediation of cell death by poly(ADP-ribose) polymerase-1. *Pharmacological Research*, **2005**, 52, 5-14	10.2	199
286	Poly(ADP-ribose) drives pathologic □synuclein neurodegeneration in Parkinson's disease. *Science*, **2018**, 362,	33.3	196
285	NMDA but not non-NMDA excitotoxicity is mediated by Poly(ADP-ribose) polymerase. *Journal of Neuroscience*, **2000**, 20, 8005-11	6.6	194
284	MicroRNA-223 is neuroprotective by targeting glutamate receptors. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 18962-7	11.5	190
283	Free radicals as mediators of neuronal injury. *Cellular and Molecular Neurobiology*, **1998**, 18, 667-82	4.6	187
282	Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. *Human Molecular Genetics*, **2005**, 14, 2571-86	5.6	183
281	Nitric oxide mediates N-methyl-D-aspartate receptor-induced activation of p21ras. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 5773-8	11.5	183
280	Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease. *Cell*, **2014**, 157, 472-485	56.2	182
279	Neuronal (type I) nitric oxide synthase regulates nuclear factor kappaB activity and immunologic (type II) nitric oxide synthase expression. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 2676-80	11.5	177

278	Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. *Human Molecular Genetics*, **2005**, 14, 3885-97	5.6	176
277	A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization. *Journal of Neurochemistry*, **2003**, 87, 1558-67	6	173
276	Nuclear targeting of mutant Huntingtin increases toxicity. *Molecular and Cellular Neurosciences*, **1999**, 14, 121-8	4.8	166
275	Characterization of polyamines having agonist, antagonist, and inverse agonist effects at the polyamine recognition site of the NMDA receptor. *Neuron*, **1990**, 5, 199-208	13.9	166
274	Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. *Journal of Neuroscience*, **2009**, 29, 11257-62	6.6	165
273	Poly(ADP-ribose) polymerase-1 and apoptosis inducing factor in neurotoxicity. *Neurobiology of Disease*, **2003**, 14, 303-17	7.5	165
272	A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1. *Science*, **2016**, 354,	33.3	165
271	GTPase activity plays a key role in the pathobiology of LRRK2. *PLoS Genetics*, **2010**, 6, e1000902	6	163
270	Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 14103-8	11.5	162
269	CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 2897-902	11.5	160
268	The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. *Journal of Neuroscience*, **2008**, 28, 3384-91	6.6	158
267	The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. *Trends in Neurosciences*, **2001**, 24, S7-14	13.3	158
266	Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death. *Nature Medicine*, **2011**, 17, 692-9	50.5	157
265	Nitric oxide actions in neurochemistry. *Neurochemistry International*, **1996**, 29, 97-110	4.4	157
264	Rare genetic mutations shed light on the pathogenesis of Parkinson disease. *Journal of Clinical Investigation*, **2003**, 111, 145-151	15.9	152
263	The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. *Trends in Neurosciences*, **2001**, 24, 7-14	13.3	151
262	Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 11696-701	11.5	149
261	Dynamic regulation of neuronal NO synthase transcription by calcium influx through a CREB family transcription factor-dependent mechanism. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 8617-22	11.5	149

260	Deadly conversations: nuclear-mitochondrial cross-talk. *Journal of Bioenergetics and Biomembranes*, **2004**, 36, 287-94	3.7	146
259	The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. *Scientific Reports*, **2014**, 4, 4874	4.9	145
258	Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. *Nature Neuroscience*, **2013**, 16, 1392-400	25.5	142
257	Neuroprotective and neurorestorative strategies for Parkinson's disease. *Nature Neuroscience*, **2002**, 5 Suppl, 1058-61	25.5	139
256	Nitric oxide synthase: role as a transmitter/mediator in the brain and endocrine system. *Annual Review of Medicine*, **1996**, 47, 219-27	17.4	133
255	Autophagy-mediated clearance of aggresomes is not a universal phenomenon. *Human Molecular Genetics*, **2008**, 17, 2570-82	5.6	130
254	Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin. *Proceedings of the National Academy of Sciences of the United States of America*, **1996**, 93, 5037-42	11.5	129
253	Role of nitric oxide in Parkinson's disease **2006**, 109, 33-41		127
252	Cyclic nucleotide dependent phosphorylation of neuronal nitric oxide synthase inhibits catalytic activity. *Neuropharmacology*, **1994**, 33, 1245-51	5.5	126
251	Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. *Brain Research*, **2007**, 1155, 208-19	3.7	125
250	Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease. *Hepatology*, **2004**, 39, 403-11	11.2	124
249	S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 4900-5	11.5	123
248	Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. *Journal of Biological Chemistry*, **2003**, 278, 48120-8	5.4	123
247	Urinary bladder-urethral sphincter dysfunction in mice with targeted disruption of neuronal nitric oxide synthase models idiopathic voiding disorders in humans. *Nature Medicine*, **1997**, 3, 571-4	50.5	121
246	Dynamic and redundant regulation of LRRK2 and LRRK1 expression. *BMC Neuroscience*, **2007**, 8, 102	3.2	121
245	Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. *British Journal of Pharmacology*, **2018**, 175, 192-222	8.6	120
244	Poly(ADP-ribose) polymerase impairs early and long-term experimental stroke recovery. *Stroke*, **2002**, 33, 1101-6	6.7	117
243	Parkin-associated Parkinson's disease. *Cell and Tissue Research*, **2004**, 318, 175-84	4.2	116

242	Reprogramming cellular events by poly(ADP-ribose)-binding proteins. *Molecular Aspects of Medicine* , **2013**, 34, 1066-87	16.7	115
241	Parkin-mediated lysine 63-linked polyubiquitination: a link to protein inclusions formation in Parkinson's and other conformational diseases?. *Neurobiology of Aging*, **2006**, 27, 524-9	5.6	114
240	Msp1/ATAD1 maintains mitochondrial function by facilitating the degradation of mislocalized tail-anchored proteins. *EMBO Journal*, **2014**, 33, 1548-64	13	113
239	LRRK2 pathobiology in Parkinson's disease. *Journal of Neurochemistry*, **2014**, 131, 554-65	6	113
238	Role of neuronal and endothelial nitric oxide synthase in nitric oxide generation in the brain following cerebral ischemia. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **1999**, 1455, 23-34	6.9	113
237	Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. *ACS Chemical Biology*, **2011**, 6, 1021-8	4.9	112
236	PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson's disease. *Molecular Neurodegeneration*, **2020**, 15, 20	19	111
235	FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 2425-30	11.5	110
234	Development and characterization of a new Parkinson's disease model resulting from impaired autophagy. *Journal of Neuroscience*, **2012**, 32, 16503-9	6.6	109
233	Nitric oxide: role in neurotoxicity. *Clinical and Experimental Pharmacology and Physiology*, **1995**, 22, 305-8	3	109
232	Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. *Human Molecular Genetics*, **2011**, 20, 3933-42	5.6	107
231	Nitric oxide in neuronal degeneration. *Experimental Biology and Medicine*, **1996**, 211, 33-40	3.7	107
230	GBA1 deficiency negatively affects physiological □synuclein tetramers and related multimers. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 798-803	11.5	106
229	Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). *Journal of Neuroscience*, **2009**, 29, 15846-50	6.6	103
228	Bcl-x is required for proper development of the mouse substantia nigra. *Journal of Neuroscience*, **2005**, 25, 6721-8	6.6	103
227	(Patho-)physiological relevance of PINK1-dependent ubiquitin phosphorylation. *EMBO Reports*, **2015**, 16, 1114-30	6.5	102
226	PINK1 Primes Parkin-Mediated Ubiquitination of PARIS in Dopaminergic Neuronal Survival. *Cell Reports*, **2017**, 18, 918-932	10.6	101
225	Apoptosis inducing factor and PARP-mediated injury in the MPTP mouse model of Parkinson's disease. *Annals of the New York Academy of Sciences*, **2003**, 991, 132-9	6.5	101

224	37-kDa laminin receptor precursor modulates cytotoxic necrotizing factor 1-mediated RhoA activation and bacterial uptake. *Journal of Biological Chemistry*, **2003**, 278, 16857-62	5.4	96
223	Toward the human cellular microRNAome. *Genome Research*, **2017**, 27, 1769-1781	9.7	95
222	MicroRNAs in Parkinson's disease. *Journal of Chemical Neuroanatomy*, **2011**, 42, 127-30	3.2	95
221	Differential susceptibility to neurotoxicity mediated by neurotrophins and neuronal nitric oxide synthase. *Journal of Neuroscience*, **1997**, 17, 4633-41	6.6	95
220	mdx muscle pathology is independent of nNOS perturbation. *Human Molecular Genetics*, **1998**, 7, 823-9	5.6	94
219	REVIEW ? : Nitric Oxide: Actions and Pathological Roles. *Neuroscientist*, **1995**, 1, 7-18	7.6	94
218	Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily. *Human Molecular Genetics*, **2014**, 23, 2055-77	5.6	93
217	Brain serotonin dysfunction accounts for aggression in male mice lacking neuronal nitric oxide synthase. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 1277-81	11.5	92
216	To die or grow: Parkinson's disease and cancer. *Trends in Neurosciences*, **2005**, 28, 348-52	13.3	91
215	Molecular mechanisms of nitric oxide actions in the brain. *Annals of the New York Academy of Sciences*, **1994**, 738, 76-85	6.5	91
214	Effects of nitric oxide on neuroendocrine function and behavior. *Frontiers in Neuroendocrinology*, **1997**, 18, 463-91	8.9	90
213	Mitochondrial Mechanisms of Neuronal Cell Death: Potential Therapeutics. *Annual Review of Pharmacology and Toxicology*, **2017**, 57, 437-454	17.9	88
212	Heterozygous PINK1 p.G411S increases risk of Parkinson's disease via a dominant-negative mechanism. *Brain*, **2017**, 140, 98-117	11.2	88
211	Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. *Journal of Neurochemistry*, **2007**, 100, 368-81	6	88
210	Activation of tyrosine kinase c-Abl contributes to □synuclein-induced neurodegeneration. *Journal of Clinical Investigation*, **2016**, 126, 2970-88	15.9	88
209	Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinson's-like movement disorder. *Nature Communications*, **2014**, 5, 4930	17.4	87
208	Animal models of Parkinson's disease: vertebrate genetics. *Cold Spring Harbor Perspectives in Medicine*, **2012**, 2,	5.4	86
207	Fyn kinase regulates misfolded □synuclein uptake and NLRP3 inflammasome activation in microglia. *Journal of Experimental Medicine*, **2019**, 216, 1411-1430	16.6	85

206	Inhibition of Neuronal Nitric Oxide Synthase Increases Aggressive Behavior in Mice. *Molecular Medicine*, **1997**, 3, 610-616	6.2	84
205	Identification of far upstream element-binding protein-1 as an authentic Parkin substrate. *Journal of Biological Chemistry*, **2006**, 281, 16193-6	5.4	84
204	ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2. *Journal of Neuroscience*, **2012**, 32, 3877-86	6.6	81
203	Parkin mediates the degradation-independent ubiquitination of Hsp70. *Journal of Neurochemistry*, **2008**, 105, 1806-19	6	81
202	Lack of involvement of neuronal nitric oxide synthase in the pathogenesis of a transgenic mouse model of familial amyotrophic lateral sclerosis. *Neuroscience*, **1999**, 90, 1483-92	3.9	79
201	MicroRNA-132 dysregulation in Toxoplasma gondii infection has implications for dopamine signaling pathway. *Neuroscience*, **2014**, 268, 128-38	3.9	77
200	Calpain activation is not required for AIF translocation in PARP-1-dependent cell death (parthanatos). *Journal of Neurochemistry*, **2009**, 110, 687-96	6	77
199	Neuroprotective effect of sigma(1)-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) is linked to reduced neuronal nitric oxide production. *Stroke*, **2001**, 32, 1613-20	6.7	77
198	Neuroimmunophilins: novel neuroprotective and neuroregenerative targets. *Annals of Neurology*, **2001**, 50, 6-16	9.4	75
197	Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy. *Journal of Neuroscience*, **2006**, 26, 3685-96	6.6	72
196	Evidence for dopamine D-2 receptors on cholinergic interneurons in the rat caudate-putamen. *Life Sciences*, **1988**, 42, 1933-9	6.8	72
195	What causes cell death in Parkinson's disease?. *Annals of Neurology*, **2008**, 64 Suppl 2, S3-15	9.4	71
194	Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations. *Journal of Biological Chemistry*, **2007**, 282, 12310-8	5.4	71
193	TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF. *Brain*, **2015**, 138, 3610-22	11.2	69
192	Neurodegenerative phenotypes in an A53T □synuclein transgenic mouse model are independent of LRRK2. *Human Molecular Genetics*, **2012**, 21, 2420-31	5.6	69
191	Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. *European Journal of Neuroscience*, **2001**, 13, 1683-93	3.5	69
190	Cell Death Mechanisms of Neurodegeneration. *Advances in Neurobiology*, **2017**, 15, 403-425	2.1	68
189	Enhanced autophagy from chronic toxicity of iron and mutant A53T □synuclein: implications for neuronal cell death in Parkinson disease. *Journal of Biological Chemistry*, **2011**, 286, 33380-9	5.4	68

188	Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity. *Journal of Biological Chemistry*, **2003**, 278, 13047-55	5.4	68
187	Meta-Analysis of the Alzheimer's Disease Human Brain Transcriptome and Functional Dissection in Mouse Models. *Cell Reports*, **2020**, 32, 107908	10.6	68
186	The AAA+ ATPase Thorase regulates AMPA receptor-dependent synaptic plasticity and behavior. *Cell*, **2011**, 145, 284-99	56.2	67
185	A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism. *Journal of Neurochemistry*, **2002**, 83, 186-92	6	67
184	EndoG is dispensable in embryogenesis and apoptosis. *Cell Death and Differentiation*, **2006**, 13, 1147-55	12.7	66
183	Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. *Molecular Neurodegeneration*, **2009**, 4, 34	19	65
182	Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease. *Journal of Neuropathology and Experimental Neurology*, **2009**, 68, 994-1005	3.1	65
181	Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases. *Cell Death and Differentiation*, **2018**, 25, 542-572	12.7	64
180	Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. *Molecular Neurodegeneration*, **2018**, 13, 1	19	63
179	Neuroprotective effects of gangliosides may involve inhibition of nitric oxide synthase. *Annals of Neurology*, **1995**, 37, 115-8	9.4	63
178	Parkin plays a role in sporadic Parkinson's disease. *Neurodegenerative Diseases*, **2014**, 13, 69-71	2.3	62
177	Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. *Trends in Pharmacological Sciences*, **2012**, 33, 365-73	13.2	62
176	Normalization of subtype-specific muscarinic receptor binding in the denervated hippocampus by septodiagonal band grafts. *Experimental Neurology*, **1989**, 106, 115-24	5.7	61
175	Rare genetic mutations shed light on the pathogenesis of Parkinson disease. *Journal of Clinical Investigation*, **2003**, 111, 145-51	15.9	61
174	Adult Conditional Knockout of PGC-1Leads to Loss of Dopamine Neurons. *ENeuro*, **2016**, 3,	3.9	61
173	Outer mitochondrial membrane localization of apoptosis-inducing factor: mechanistic implications for release. *ASN Neuro*, **2009**, 1,	5.3	59
172	Microglia and astrocyte dysfunction in parkinson's disease. *Neurobiology of Disease*, **2020**, 144, 105028	7.5	59
171	Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration. *Molecular Neurodegeneration*, **2018**, 13, 8	19	58

170	Aggressive behavior in male mice lacking the gene for neuronal nitric oxide synthase requires testosterone. *Brain Research*, **1997**, 769, 66-70	3.7	58
169	MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. *Neurobiology of Disease*, **2007**, 26, 312-22	7.5	58
168	Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease. *Molecular Brain Research*, **2005**, 134, 103-8		55
167	Differential effect of PARP-2 deletion on brain injury after focal and global cerebral ischemia. *Journal of Cerebral Blood Flow and Metabolism*, **2006**, 26, 135-41	7.3	54
166	Identification and analysis of plasticity-induced late-response genes. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 2145-50	11.5	54
165	Neuroprotective FK506 does not alter in vivo nitric oxide production during ischemia and early reperfusion in rats. *Stroke*, **1999**, 30, 1279-85	6.7	54
164	Functional recovery of supersensitive dopamine receptors after intrastriatal grafts of fetal substantia nigra. *Experimental Neurology*, **1991**, 111, 282-92	5.7	54
163	Cultured networks of excitatory projection neurons and inhibitory interneurons for studying human cortical neurotoxicity. *Science Translational Medicine*, **2016**, 8, 333ra48	17.5	52
162	Physiological and toxicological actions of nitric oxide in the central nervous system. *Advances in Pharmacology*, **1995**, 34, 323-42	5.7	52
161	LRRK2 affects vesicle trafficking, neurotransmitter extracellular level and membrane receptor localization. *PLoS ONE*, **2013**, 8, e77198	3.7	51
160	Neuronal ischaemic preconditioning. *Trends in Pharmacological Sciences*, **2000**, 21, 423-4	13.2	51
159	Resistance to MPTP-neurotoxicity in □synuclein knockout mice is complemented by human □synuclein and associated with increased □synuclein and Akt activation. *PLoS ONE*, **2011**, 6, e16706	3.7	50
158	Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. *Neurobiology of Disease*, **2014**, 71, 345-58	7.5	49
157	Protein microarray characterization of the S-nitrosoproteome. *Molecular and Cellular Proteomics*, **2014**, 13, 63-72	7.6	49
156	Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease. *Free Radical Biology and Medicine*, **2009**, 47, 1049-56	7.8	49
155	Lysine 63-linked polyubiquitin potentially partners with p62 to promote the clearance of protein inclusions by autophagy. *Autophagy*, **2008**, 4, 251-253	10.2	48
154	Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death. *Neurobiology of Aging*, **2007**, 28, 1709-17	5.6	47
153	Role for the ubiquitin-proteasome system in Parkinson's disease and other neurodegenerative brain amyloidoses. *NeuroMolecular Medicine*, **2003**, 4, 95-108	4.6	47

152	Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes. *Experimental Neurology*, **2017**, 298, 191-201	5.7	45
151	Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 1635-1640	11.5	45
150	Neuronal activity regulates hippocampal miRNA expression. *PLoS ONE*, **2011**, 6, e25068	3.7	45
149	The interplay of microRNA and neuronal activity in health and disease. *Frontiers in Cellular Neuroscience*, **2013**, 7, 136	6.1	44
148	Contributions of poly(ADP-ribose) polymerase-1 and -2 to nuclear translocation of apoptosis-inducing factor and injury from focal cerebral ischemia. *Journal of Neurochemistry*, **2010**, 113, 1012-22	6	44
147	Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2. *Journal of Biological Chemistry*, **2010**, 285, 29569-76	5.4	42
146	Stroke outcome in double-mutant antioxidant transgenic mice. *Stroke*, **2000**, 31, 2685-91	6.7	42
145	Nitric Oxide Signaling in Neurodegeneration and Cell Death. *Advances in Pharmacology*, **2018**, 82, 57-83	5.7	41
144	c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential. *Journal of Parkinson's Disease*, **2017**, 7, 589-601	5.3	41
143	Pathological Endogenous β-Synuclein Accumulation in Oligodendrocyte Precursor Cells Potentially Induces Inclusions in Multiple System Atrophy. *Stem Cell Reports*, **2018**, 10, 356-365	8	40
142	NMDA-induced neuronal survival is mediated through nuclear factor I-A in mice. *Journal of Clinical Investigation*, **2010**, 120, 2446-56	15.9	39
141	BAD is a pro-survival factor prior to activation of its pro-apoptotic function. *Journal of Biological Chemistry*, **2004**, 279, 42240-9	5.4	39
140	The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity. *Molecular Neurodegeneration*, **2017**, 12, 32	19	37
139	The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration. *Movement Disorders*, **2019**, 34, 959-969	7	37
138	Botch promotes neurogenesis by antagonizing Notch. *Developmental Cell*, **2012**, 22, 707-20	10.2	37
137	Influence of duration of focal cerebral ischemia and neuronal nitric oxide synthase on translocation of apoptosis-inducing factor to the nucleus. *Neuroscience*, **2007**, 144, 56-65	3.9	37
136	Models of LRRK2-Associated Parkinson's Disease. *Advances in Neurobiology*, **2017**, 14, 163-191	2.1	36
135	Involvement of poly ADP ribosyl polymerase-1 in acute but not chronic zinc toxicity. *European Journal of Neuroscience*, **2003**, 18, 1402-9	3.5	34

134	Muscarinic and dopaminergic receptor subtypes on striatal cholinergic interneurons. *Brain Research Bulletin*, **1990**, 25, 903-12	3.9	34
133	S-nitrosylation in Parkinson's disease and related neurodegenerative disorders. *Methods in Enzymology*, **2005**, 396, 139-50	1.7	33
132	Spatial and functional relationship between poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in the brain. *Neuroscience*, **2007**, 148, 198-211	3.9	32
131	The cast of molecular characters in Parkinson's disease: felons, conspirators, and suspects. *Annals of the New York Academy of Sciences*, **2003**, 991, 80-92	6.5	32
130	New insights into Parkinson's disease. *Journal of Neurology*, **2003**, 250 Suppl 3, III15-24	5.5	32
129	Synaptic Plasticity onto Dopamine Neurons Shapes Fear Learning. *Neuron*, **2017**, 93, 425-440	13.9	31
128	PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency. *Molecular Neurodegeneration*, **2020**, 15, 17	19	31
127	Identification through high-throughput screening of 4'-methoxyflavone and 3',4'-dimethoxyflavone as novel neuroprotective inhibitors of parthanatos. *British Journal of Pharmacology*, **2013**, 169, 1263-78	8.6	31
126	Glutamate-stimulated calcium activation of Ras/Erk pathway mediated by nitric oxide. *Diabetes Research and Clinical Practice*, **1999**, 45, 113-5	7.4	31
125	Nanozyme scavenging ROS for prevention of pathologic □synuclein transmission in Parkinson□ disease. *Nano Today*, **2021**, 36, 101027	17.9	31
124	Activation mechanisms of the E3 ubiquitin ligase parkin. *Biochemical Journal*, **2017**, 474, 3075-3086	3.8	30
123	Proneural transcription factor Atoh1 drives highly efficient differentiation of human pluripotent stem cells into dopaminergic neurons. *Stem Cells Translational Medicine*, **2014**, 3, 888-98	6.9	30
122	New synaptic and molecular targets for neuroprotection in Parkinson's disease. *Movement Disorders*, **2013**, 28, 51-60	7	30
121	Identification of calcium- and nitric oxide-regulated genes by differential analysis of library expression (DAzLE). *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 647-52	11.5	30
120	ADP-ribosyltransferases, an update on function and nomenclature. *FEBS Journal*, **2021**,	5.7	30
119	Ganglioside regulation of AMPA receptor trafficking. *Journal of Neuroscience*, **2014**, 34, 13246-58	6.6	29
118	LRRK2 G2019S transgenic mice display increased susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated neurotoxicity. *Journal of Chemical Neuroanatomy*, **2016**, 76, 90-97	3.2	29
117	The involvement of nitric oxide in the enhanced expression of mu-opioid receptors during intestinal inflammation in mice. *British Journal of Pharmacology*, **2005**, 145, 758-66	8.6	28

116	Synthetic mRNAs Drive Highly Efficient iPS Cell Differentiation to Dopaminergic Neurons. *Stem Cells Translational Medicine*, **2019**, 8, 112-123	6.9	28
115	Precision therapy for a new disorder of AMPA receptor recycling due to mutations in. *Neurology: Genetics*, **2017**, 3, e130	3.8	27
114	The genetics of Parkinson's disease. *Current Neurology and Neuroscience Reports*, **2002**, 2, 439-46	6.6	27
113	Poly (ADP-ribose) (PAR)-dependent cell death in neurodegenerative diseases. *International Review of Cell and Molecular Biology*, **2020**, 353, 1-29	6	26
112	DISC1 regulates lactate metabolism in astrocytes: implications for psychiatric disorders. *Translational Psychiatry*, **2018**, 8, 76	8.6	26
111	A homozygous ATAD1 mutation impairs postsynaptic AMPA receptor trafficking and causes a lethal encephalopathy. *Brain*, **2018**, 141, 651-661	11.2	26
110	The impact of genetic research on our understanding of Parkinson's disease. *Progress in Brain Research*, **2010**, 183, 21-41	2.9	26
109	Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity. *Human Molecular Genetics*, **2012**, 21, 163-74	5.6	26
108	Lessons from Drosophila models of DJ-1 deficiency. *Science of Aging Knowledge Environment: SAGE KE*, **2006**, 2006, pe2		26
107	Functional identification of neuroprotective molecules. *PLoS ONE*, **2010**, 5, e15008	3.7	26
106	Early-onset Parkinson's disease due to PINK1 p.Q456X mutation--clinical and functional study. *Parkinsonism and Related Disorders*, **2014**, 20, 1274-8	3.6	25
105	Advances in neuronal cell death 2007. *Stroke*, **2008**, 39, 286-8	6.7	25
104	Determinants of seeding and spreading of □synuclein pathology in the brain. *Science Advances*, **2020**, 6,	14.3	25
103	Glial pathology and retinal neurotoxicity in the anterior visual pathway in experimental autoimmune encephalomyelitis. *Acta Neuropathologica Communications*, **2019**, 7, 125	7.3	24
102	The orphan nuclear receptor, steroidogenic factor 1, regulates neuronal nitric oxide synthase gene expression in pituitary gonadotropes. *Molecular Endocrinology*, **2002**, 16, 2828-39		24
101	Botch is a □glutamyl cyclotransferase that deglycinates and antagonizes Notch. *Cell Reports*, **2014**, 7, 681-8	10.6	23
100	Promising disease-modifying therapies for Parkinson's disease. *Science Translational Medicine*, **2019** , 11,	17.5	22
99	Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson's disease. *Brain*, **2019**, 142, 2380-2401	11.2	21

98	MiR-223 regulates the differentiation of immature neurons. *Molecular and Cellular Therapies*, **2014**, 2,		21
97	LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease. *Biochemical Society Transactions*, **2012**, 40, 1074-9	5.1	21
96	gp120 neurotoxicity in primary cortical cultures. *Advances in Neuroimmunology*, **1994**, 4, 167-73		21
95	Alterations in cortical muscarinic receptors following cholinotoxin (AF64A) lesion of the rat nucleus basalis magnocellularis. *Neurobiology of Aging*, **1992**, 13, 25-32	5.6	21
94	Downregulation of muscarinic receptors in the rat caudate-putamen after lesioning of the ipsilateral nigrostriatal dopamine pathway with 6-hydroxydopamine (6-OHDA): normalization by fetal mesencephalic transplants. *Brain Research*, **1991**, 540, 145-52	3.7	21
93	Defects in Mitochondrial Biogenesis Drive Mitochondrial Alterations in PARKIN-Deficient Human Dopamine Neurons. *Stem Cell Reports*, **2020**, 15, 629-645	8	21
92	Neonatal stroke in mice causes long-term changes in neuronal Notch-2 expression that may contribute to prolonged injury. *Stroke*, **2010**, 41, S64-71	6.7	20
91	Comment on "S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function". *Science*, **2005**, 308, 1870; author reply 1870	33.3	20
90	Impaired Ovulation in Mice with Targeted Deletion of the Neuronal Isoform of Nitric Oxide Synthase. *Molecular Medicine*, **1998**, 4, 658-664	6.2	20
89	Motor neuron death in ALS: programmed by astrocytes?. *Neuron*, **2014**, 81, 961-963	13.9	19
88	Nitric Oxide: Diverse Actions in the Central and Peripheral Nervous Systems. *Neuroscientist*, **1998**, 4, 96-112	1.2	19
87	Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and Synuclein Pathology. *ENeuro*, **2017**, 4,	3.9	19
86	Two approaches reveal a new paradigm of 'switchable or genetics-influenced allele-specific DNA methylation' with potential in human disease. *Cell Discovery*, **2017**, 3, 17038	22.3	18
85	Augmentation of poly(ADP-ribose) polymerase-dependent neuronal cell death by acidosis. *Journal of Cerebral Blood Flow and Metabolism*, **2017**, 37, 1982-1993	7.3	17
84	The road to survival goes through PARG. *Cell Cycle*, **2005**, 4, 397-9	4.7	17
83	Hippocampal muscarinic supersensitivity after AF64A medial septal lesion excludes M1 receptors. *Brain Research Bulletin*, **1990**, 25, 311-7	3.9	16
82	Endonuclease G does not play an obligatory role in poly(ADP-ribose) polymerase-dependent cell death after transient focal cerebral ischemia. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2010**, 299, R215-21	3.2	15
81	The cell biology of Parkinson's disease. *Journal of Cell Biology*, **2021**, 220,	7.3	15

80	Abberant protein synthesis in G2019S LRRK2 Drosophila Parkinson disease-related phenotypes. *Fly*, **2014**, 8, 165-9	1.3	14
79	What have genetically engineered mice taught us about ischemic injury?. *Current Molecular Medicine*, **2004**, 4, 207-25	2.5	14
78	Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer's disease. *Acta Neuropathologica Communications*, **2021**, 9, 78	7.3	14
77	Parkin: clinical aspects and neurobiology. *Clinical Neuroscience Research*, **2001**, 1, 467-482		13
76	Receptor alterations in subcortical structures after bilateral middle cerebral artery infarction of the cerebral cortex. *Experimental Neurology*, **1994**, 128, 88-96	5.7	13
75	Defects in mRNA Translation in LRRK2-Mutant hiPSC-Derived Dopaminergic Neurons Lead to Dysregulated Calcium Homeostasis. *Cell Stem Cell*, **2020**, 27, 633-645.e7	18	13
74	Mechanistic basis for receptor-mediated pathological □synuclein fibril cell-to-cell transmission in Parkinson's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	13
73	Thorase variants are associated with defects in glutamatergic neurotransmission that can be rescued by Perampanel. *Science Translational Medicine*, **2017**, 9,	17.5	12
72	SnapShot: pathogenesis of Parkinson's disease. *Cell*, **2009**, 139, 440.e1-2	56.2	12
71	Recent advances in our understanding of Parkinson's disease. *Drug Discovery Today Disease Mechanisms*, **2005**, 2, 427-433		12
70	High-Content Genome-Wide RNAi Screen Reveals as a Key Mediator of Neuronal Cell Death. *ENeuro* , **2016**, 3,	3.9	10
69	Lysosomal Enzyme Glucocerebrosidase Protects against A□1-42 Oligomer-Induced Neurotoxicity. *PLoS ONE*, **2015**, 10, e0143854	3.7	9
68	A lysosomal lair for a pathogenic protein pair. *Science Translational Medicine*, **2011**, 3, 91ps28	17.5	9
67	Neurons Derived from Human Induced Pluripotent Stem Cells Integrate into Rat Brain Circuits and Maintain Both Excitatory and Inhibitory Synaptic Activities. *ENeuro*, **2019**, 6,	3.9	9
66	Lymphocyte Activation Gene 3 (Lag3) Contributes to □Synucleinopathy in □Synuclein Transgenic Mice. *Frontiers in Cellular Neuroscience*, **2021**, 15, 656426	6.1	8
65	Reduction of functional N-methyl-D-aspartate receptors in neurons by RNase P-mediated cleavage of the NR1 mRNA. *Journal of Neurochemistry*, **2001**, 76, 1386-94	6	7
64	Large-scale phenotypic drug screen identifies neuroprotectants in zebrafish and mouse models of retinitis pigmentosa. *ELife*, **2021**, 10,	8.9	6
63	PARIS farnesylation prevents neurodegeneration in models of Parkinson's disease. *Science Translational Medicine*, **2021**, 13,	17.5	6

62	Usp16: key controller of stem cells in Down syndrome. *EMBO Journal*, **2013**, 32, 2788-9	13	5
61	Histochemical analysis of nitric oxide synthase by NADPH diaphorase staining. *Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al]*, **2001**, Chapter 10, Unit 10.6	1	5
60	Nitric Oxide Synthase Inhibitors. *CNS Drugs*, **1996**, 6, 351-357	6.7	5
59	The AAA + ATPase Thorase is neuroprotective against ischemic injury. *Journal of Cerebral Blood Flow and Metabolism*, **2019**, 39, 1836-1848	7.3	5
58	STING mediates neurodegeneration and neuroinflammation in nigrostriatal □synucleinopathy.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2118819119	11.5	5
57	AMPA Receptor Surface Expression Is Regulated by S-Nitrosylation of Thorase and Transnitrosylation of NSF. *Cell Reports*, **2020**, 33, 108329	10.6	4
56	Mining for survival genes. *Biochemical Society Transactions*, **2006**, 34, 1307-9	5.1	4
55	Neurotoxic Actions and Mechanisms of Nitric Oxide **2000**, 695-710		4
54	Complement and Coagulation Cascades are Potentially Involved in Dopaminergic Neurodegeneration in □synuclein-Based Mouse Models of Parkinson's Disease. *Journal of Proteome Research*, **2021**, 20, 3428-3443	5.6	4
53	Quantitative mass spectrometric analysis of the mouse cerebral cortex after ischemic stroke. *PLoS ONE*, **2020**, 15, e0231978	3.7	4
52	Influence of Nitric Oxide on Neuroendocrine Function and Behavior **2000**, 429-438		3
51	Aplp1 and the Aplp1-Lag3 Complex facilitates transmission of pathologic □synuclein		3
50	Targeting Parthanatos in Ischemic Stroke. *Frontiers in Neurology*, **2021**, 12, 662034	4.1	3
49	LRRK2 pathobiology in Parkinson's disease - virtual inclusion. *Journal of Neurochemistry*, **2016**, 139 Suppl 1, 75-76	6	3
48	PARP and the Release of Apoptosis-Inducing Factor from Mitochondria **2006**, 103-117		3
47	Reply: Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder. *Brain*, **2017**, 140, e33	11.2	2
46	Development of a novel method for the quantification of tyrosine 39 phosphorylated □and □synuclein in human cerebrospinal fluid. *Clinical Proteomics*, **2020**, 17, 13	5	2
45	Excitotoxic Programmed Cell Death Involves Caspase-Independent Mechanisms **2018**, 3-17		2

44	NADPH Diaphorase Staining. *Methods in Neurosciences*, **1996**, 31, 62-67		2
43	Nitric Oxide Toxicity in Central Nervous System Cultures. *Methods in Neurosciences*, **1996**, 30, 26-43		2
42	Generation of isoform-specific antibodies to nitric oxide synthases. *Methods in Enzymology*, **1996**, 268, 349-58	1.7	2
41	Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection. *Pharmacological Reviews*, **2021**, 73, 33-97	22.5	2
40	Measuring the activity of leucine-rich repeat kinase 2: a kinase involved in Parkinson's disease. *Methods in Molecular Biology*, **2012**, 795, 45-54	1.4	2
39	Complement and coagulation cascades are potentially involved in dopaminergic neurodegeneration in □synuclein-based mouse models of Parkinson□ disease		2
38	Genomics-Proteomics and Stroke: Introduction. *Stroke*, **2004**, 35, 2731-2734	6.7	1
37	Identification and evaluation of NO-regulated genes by differential analysis of primary cDNA library expression (DAzLE). *Methods in Enzymology*, **2005**, 396, 359-68	1.7	1
36	Function of Nitric Oxide in Neuronal Cell Death. *Methods in Neurosciences*, **1996**, 228-240		1
35	Waiting for PARIS-A Biological Target in Search of a Drug. *Journal of Parkinson's Disease*, **2021**,	5.3	1
34	Integrative genome-wide analysis of dopaminergic neuron-specific PARIS expression in Drosophila dissects recognition of multiple PPAR-□associated gene regulation. *Scientific Reports*, **2021**, 11, 21500	4.9	1
33	TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson's disease. *Neuron*, **2021**, 109, 3758-3774.e11	13.9	1
32	Experience-dependent translational state defined by cell type-specific ribosome profiling		1
31	Molecular Mediation of Prion-like □Synuclein Fibrillation from Toxic PFFs to Nontoxic Species.. *ACS Applied Bio Materials*, **2020**, 3, 6096-6102	4.1	1
30	Host regulator PARP1 contributes to sex differences and immune responses in a mouse model of tuberculosis		1
29	Protocol for measurement of calcium dysregulation in human induced pluripotent stem cell-derived dopaminergic neurons. *STAR Protocols*, **2021**, 2, 100405	1.4	1
28	Reply: ATAD1 encephalopathy and stiff baby syndrome: a recognizable clinical presentation. *Brain*, **2018**, 141, e50	11.2	1
27	USP39 promotes non-homologous end-joining repair by poly(ADP-ribose)-induced liquid demixing. *Nucleic Acids Research*, **2021**, 49, 11083-11102	20.1	1

26	Recent advances in preventing neurodegenerative diseases.. *Faculty Reviews*, **2021**, 10, 81	1.2	1
25	Parthanatos **2008**, 143-156		0
24	Excitotoxic Programmed Cell Death Involves Caspase-Independent Mechanisms **2010**, 79-88		0
23	AIF3 splicing switch triggers neurodegeneration. *Molecular Neurodegeneration*, **2021**, 16, 25	19	0
22	Interleukin-6 triggers toxic neuronal iron sequestration in response to pathological □synuclein.. *Cell Reports*, **2022**, 38, 110358	10.6	0
21	Deubiquitinase CYLD acts as a negative regulator of dopamine neuron survival in Parkinson's disease.. *Science Advances*, **2022**, 8, eabh1824	14.3	0
20	A high-affinity cocaine binding site associated with the brain acid soluble protein 1.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2200545119	11.5	0
19	Intracellular Signaling: Mediators and Protective Responses **2016**, 80-89		
18	Parkinson Disease: Molecular Insights **2007**, 221-239		
17	Poly (ADP-ribose) polymerase and brain ischemia. *International Congress Series*, **2003**, 1252, 21-29		
16	The role of nitric oxide and PARP in neuronal cell death **2005**, 146-156		
15	Mechanisms of ischemic tolerance **2002**, 58-71		
14	Overview of the pathway and functions of nitric oxide. *Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al]*, **2001**, Chapter 10, Unit 10.1	1	
13	Ubiquitination by Parkin □mplications in Parkinson□ Disease **2006**, 213-224		
12	Intracellular Signaling: Mediators and Protective Responses **2004**, 895-902		
11	Genetics Of Parkinson□ Disease. *Neurological Disease and Therapy*, **2005**, 611-631		
10	Parkin and Neurodegeneration211-236		
9	Genetic Models of Familial Parkinson's Disease **2008**, 225-236		

8	Integration of Human Induced Pluripotent Stem Cell (hiPSC)-Derived Neurons into Rat Brain Circuits. *Bio-protocol*, **2020**, 10, e3746	0.9
7	Reversal of nigrostriatal-lesion-induced receptor alterations by grafting of fetal mesencephalic dopaminergic neurons. *Advances in Experimental Medicine and Biology*, **1991**, 287, 221-35	3.6
6	Nitric Oxide Neurotoxicity in Primary Neuronal Cultures **1995**, 3-15	
5	Nitric Oxide Actions in the Nervous System **1996**, 247-262	
4	Intracellular Signaling: Mediators and Protective Responses **2011**, 154-161	
3	The PINK1 p.I368N Mutation Affects Protein Stability and Kinase Activity with Its Structural Change. *Juntendo Medical Journal*, **2018**, 64, 17-30	0.1
2	Intracellular Signaling: Mediators and Protective Responses **2022**, 74-81.e5	
1	Parkin and Neurodegeneration211-236	